| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | KAT2B; PCAF; Histone acetyltransferase KAT2B; Histone acetyltransferase PCAF; Histone acetylase PCAF; Lysine acetyltransferase 2B; P300/CBP-associated factor; P/CAF |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human p300/CBP. AA range:783-832 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Storage |
Product Overview
Research Use OnlyCBP and p300 are large nuclear proteins that bind to many sequence-specific factors involved in cell growth and/or differentiation, including c-jun and the adenoviral oncoprotein E1A. Lysine acetyltransferase 2B encoded by KAT2B associates with p300/CBP. It has in vitro and in vivo binding activity with CBP and p300, and competes with E1A for binding sites in p300/CBP.
Validated Applications
| Western Blot (WB) | See datasheet for recommended dilution |
|---|---|
| Immunohistochemistry (IHC) | See datasheet for recommended dilution |
| ELISA (ELISA) | See datasheet for recommended dilution |
Key Specifications
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Species Reactivity | Human, Mouse, Rat |
| Isotype | IgG |
| Purification | Affinity Purification |
| Concentration | 1 mg/ml |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Molecular Weight | 93013 Da |
| Catalog No. | BT-AP06968 |
| UniProt | Human: Q92831; Mouse: Q9JHD1 |
| Alternative Names | KAT2B; PCAF; Histone acetyltransferase KAT2B; Histone acetyltransferase PCAF; Histone acetylase PCAF; Lysine acetyltransferase 2B; P300/CBP-associated factor; P/CAF |
Immunogen / Antigen
The antiserum was produced against synthesized peptide derived from human p300/CBP. AA range:783-832
Reactivity Notes
This antibody has been validated for reactivity against Human, Mouse, Rat targets. Cross-reactivity with other species may exist but has not been formally established.
Storage & Handling
-20°C for 1 year
Safety
For Research Use Only (RUO). Not intended for diagnostic, therapeutic, or veterinary use. Handle according to standard laboratory biosafety guidelines. Avoid skin and eye contact. Dispose of waste in accordance with local regulations.
All of antibodies are generated with peptides designed using the database corresponding to the primary species listed in the datasheet. Generally they are human, mouse or rat. This species was then confirmed with the western blot validation data shown for each antibody in the appropriate species. If we do not obtain positive results in one species, we do not list that species. But the cell line we test possibly contains a low level of particular protein or the inductions we used do not work in that particular cell line. We suggest you compare the peptide sequence between the species you are studying and the species that BT Lab's antibody was raised against. In most cases, BT Lab's antibodies are raised against the human protein sequence and are highly purified using affinity chromatography.
The instruction specifies the intended use for BT Lab's antibody. Any procedure not specified in the instruction should be validated by user.
Generally BT Lab offers antibodies with a purity higher than 96%.
Please store the antibody at -20°C.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
